Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Lupin Limited

http://www.lupin.com

Latest From Lupin Limited

Zydus Q1: Novel Molecule Enters Phase I, Global Biosimilar Strategy To Shift?

Bookmark
  • Analysis
By Vibha Ravi

Zydus has begun Phase I trials for an anti-properdin drug in India while its sitagliptin franchise in US, distinct from Merck’s Januvia and Janumet, looks promising. Meanwhile MD Sharvil Patel says a biosimilars entry in developed markets is possible if certain conditions are met.

Sales & Earnings Strategy

Zydus Q1: Novel Molecule Enters Phase I, Global Biosimilar Strategy To Shift?

Bookmark
  • Analysis
By Vibha Ravi

Zydus has begun Phase I trials for an anti-properdin drug in India while its sitagliptin franchise in US, distinct from Merck’s Januvia and Janumet, looks promising. Meanwhile MD Sharvil Patel says a biosimilars entry in developed markets is possible if certain conditions are met.

Business Strategies Biosimilars

Deal Watch: Revance To Go Private In Crown Laboratories Buyout

Bookmark
  • News
By Joseph Haas and Vibha Ravi

Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.

Deal Watch M & A

Lupin Eyes Another Mirabegron Launch Amid Ongoing Litigation

Bookmark
  • Analysis
By Urtė Fultinavičiūtė

With a clear focus on complex products, Lupin sets out its launch plans for the year ahead, while battling ongoing litigation over some of its generics.

Sales & Earnings Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Pulmonary
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Generic Health Pty Ltd
    • Temmler Pharma GmbH & Co.
    • YL Biologics (YLB)
    • ZAO Biocom
    • Kyowa Pharmaceutical Industry Co., Ltd.
    • Southern Cross Pharma Pty Ltd
    • Symbiomix Therapeutics, LLC.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By